Ohr Pharmaceutical Issues Letter to Shareholders

NEW YORK, NY--(Marketwire - July 31, 2012) -

Ohr Pharmaceutical Inc. (OTCBB: OHRP), a pharmaceutical company dedicated to developing novel treatments for large unmet medical needs, issued the following letter to shareholders today:

Dear Shareholder,

I would like to take this opportunity to share the progress we have made and lay out the milestones we are expecting in the near term:

Key Developments

  • Strengthened balance sheet: The Company recently completed at $2.9 million dollar financing with a group of existing shareholders at favorable terms. We are now well financed to continue the clinical development of our pipeline compounds.
  • Squalamine eye drop data: We completed several preclinical studies to support our upcoming clinical trial for the treatment of wet form of macular degeneration ("wet-AMD"). The studies demonstrated:
    • Therapeutically relevant concentrations in the tissues of the back of the eye
    • The ability to maintain those concentrations consistently
    • Ocular and systemic safety when administered over a long period of time

Data was presented at the Association for Research in Vision and Ophthalmology (ARVO) conference in May. Dr. Michael Elman, a member of our scientific advisory board, also made an oral presentation, at the Macula Society 2012 meeting, which outlined the clinical relevance of Squalamine eye drops and its potential utility in neovascular ophthalmic disorders.

  • FDA Fast Track designation: In May, the U.S. FDA granted our Squalamine eye drop program with Fast Track designation for the treatment of wet-AMD. Fast track designation is awarded to programs that meet specific criteria which includes programs that demonstrate the potential to treat an unmet medical need. Fast track status will provide us with many advantages to potentially accelerate development of the Squalamine eye drop program, such as more frequent meetings with the FDA and the potential for Priority Review.
  • Formation of World Class Scientific Advisory Board: In the second quarter of 2012, we assembled an ophthalmic scientific advisory board consisting of five top thought leaders in the treatment of retinal disorders and other ophthalmology indications. These thought leaders have been actively involved in the clinical development of therapeutics approved by the FDA for wet-AMD (Lucentis ® and Eylea®), and are at the leading edge of research into novel therapeutics for retinal disorders.
  • Strengthening of patent portfolio: In the first half of 2012, we were granted several key patents on our Squalamine and OHR/AVR118 programs including composition of matter and method of use claims. Additional applications have been filed and we plan to continue expanding our intellectual property portfolio.
  • Increased market awareness and visibility: We have amplified our efforts to increase market awareness and visibility of our exciting story through road show meetings with institutional investors, presentations at investor conferences, online and print articles, and social media. We will continue our efforts in the coming months and plan to attend and present at several conferences through the end of 2012.

Expected Upcoming Events

  • Initiation of Squalamine Eye Drop Trial: We expect to initiate the Phase II trial of Squalamine eye drops for the treatment of wet-AMD before the end of the current quarter (3Q2012). The trial will be a randomized, placebo controlled trial to evaluate the efficacy and safety of Squalamine eye drops in 120 wet-AMD patients over a nine month treatment period. The study will take place at 20 treatment centers in the U.S.
  • Completion of OHR/AVR118 Trial and Data Presentation: Enrollment of the OHR/AVR118 trial is ongoing and we expect to complete enrollment by the end of 2012 and to present top line data from the phase II trial in early 2013. The interim analysis from the current trial demonstrated positive effects and mitigation of multiple symptoms of cachexia, a severe wasting disorder seen in late stage cancer patients which is highly debilitating and diminishes their quality of life. There is currently no FDA approved therapy for cancer cachexia. The trial is fully funded through its completion by our QTDP grant.
  • Uplisting to a national exchange: Based on our strengthened financial position, we are planning on initiating discussions with national exchanges to move our listing to a larger exchange within the next twelve months.

Our conversations over the past few months with physicians, patients, investors, and analysts have been very encouraging on both of our lead programs. Our programs have the ability to meet large unmet medical needs in large and growing, well established markets. Wet-AMD in particular, is an area that has received a lot of attention lately with the launch of Regeneron's (REGN) Eylea® and the continued commercial success of Roche/Genentech's (RHHBY) Lucentis®, which had combined half year 2012 revenues in excess of $2 billion.

I thank you for your ongoing support and I look forward to updating you in the future as we continue to rapidly progress with our exciting development programs.

Best regards,
Irach B. Taraporewala
Chief Executive Officer

About Ohr Pharmaceutical Inc.
Ohr Pharmaceutical Inc. (OTCBB: OHRP) (www.ohrpharmaceutical.com) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focused on two lead compounds: Squalamine eye drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia, currently being investigated in a Phase II trial.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Ohr Pharmaceutical Inc.
Investor Relations:
Tel: (877) 215-4813
Email: ir@ohrpharmaceutical.com

Digg this    Bookmark with del.icio.us    Add to Newsvine


Back to news